These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 20925049)

  • 41. Drug hypersensitivity in HIV.
    Phillips E; Mallal S
    Curr Opin Allergy Clin Immunol; 2007 Aug; 7(4):324-30. PubMed ID: 17620824
    [TBL] [Abstract][Full Text] [Related]  

  • 42. A nested sequence-specific primer-polymerase chain reaction for the detection of HLA-B*15:02.
    Virakul S; Kupatawintu P; Nakkuntod J; Kangwanshiratada O; Vilaivan T; Hirankarn N
    Tissue Antigens; 2012 Apr; 79(4):295-301. PubMed ID: 22283394
    [TBL] [Abstract][Full Text] [Related]  

  • 43. HLA-B*5701 frequency in Chilean HIV-infected patients and in general population.
    Poggi H; Vera A; Lagos M; Solari S; Rodríguez P L; Pérez CM
    Braz J Infect Dis; 2010; 14(5):510-2. PubMed ID: 21221482
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Abacavir hypersensitivity reaction.
    AIDS Patient Care STDS; 2002 May; 16(5):242. PubMed ID: 12058699
    [No Abstract]   [Full Text] [Related]  

  • 45. Genetic association studies to detect adverse drug reactions: abacavir hypersensitivity as an example.
    Hughes AR; Brothers CH; Mosteller M; Spreen WR; Burns DK
    Pharmacogenomics; 2009 Feb; 10(2):225-33. PubMed ID: 19207023
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Cost-effectiveness analysis of HLA-B*5701 typing in the prevention of hypersensitivity to abacavir in HIV+ patients in Spain.
    Nieves Calatrava D; Calle-Martín Ode L; Iribarren-Loyarte JA; Rivero-Román A; García-Bujalance L; Pérez-Escolano I; Brosa-Riestra M
    Enferm Infecc Microbiol Clin; 2010 Nov; 28(9):590-5. PubMed ID: 20144493
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [Prospective validation of a pharmacogenetic test: the PREDICT-1 study].
    Muñoz de Benito RM; Arribas López JR
    Enferm Infecc Microbiol Clin; 2008 May; 26 Suppl 6():40-4. PubMed ID: 18680695
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Direct PCR: a new pharmacogenetic approach for the inexpensive testing of HLA-B*57:01.
    Cascella R; Strafella C; Ragazzo M; Zampatti S; Borgiani P; Gambardella S; Pirazzoli A; Novelli G; Giardina E
    Pharmacogenomics J; 2015 Apr; 15(2):196-200. PubMed ID: 25201286
    [TBL] [Abstract][Full Text] [Related]  

  • 49. HLA-B*5701 screening prior to abacavir prescription: clinical and laboratory aspects.
    Nolan D
    Crit Rev Clin Lab Sci; 2009; 46(3):153-65. PubMed ID: 19514905
    [TBL] [Abstract][Full Text] [Related]  

  • 50. [Correlation, in previously treated HIV-1 positive patients, between hypersensitivity reaction to abacavir and the presence of the HLA-B*5701 allele].
    Pérez Prior N; Rocher Milla A; Soler Company E; Flores Cid J; Sarria Chust B
    Farm Hosp; 2009; 33(3):155-60. PubMed ID: 19712599
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Abacavir: pretreatment screening: warning. Encouraging method but uncertainties remain.
    Prescrire Int; 2008 Dec; 17(98):239. PubMed ID: 19422151
    [TBL] [Abstract][Full Text] [Related]  

  • 52. The frequency of HLA-B(∗)57:01 and the risk of abacavir hypersensitivity reactions in the majority population of Costa Rica.
    Arrieta-Bolaños E; Madrigal JA; Marsh SG; Shaw BE; Salazar-Sánchez L
    Hum Immunol; 2014 Nov; 75(11):1092-6. PubMed ID: 25286002
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Prevalence of HLA-B*5701 in HIV-infected patients in Spain (results of the EPI Study).
    Arrizabalaga J; Rodriguez-Alcántara F; Castañer JL; Ocampo A; Podzamczer D; Pulido F; Riera M; Sanz J; Pascual-Bernaldez M; Dal-Re R;
    HIV Clin Trials; 2009; 10(1):48-51. PubMed ID: 19362996
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Hypersensitivity reactions in patients treated with abacavir: strategies to avoid such reactions.
    Kapoor S
    AIDS Patient Care STDS; 2008 Oct; 22(10):769. PubMed ID: 18778242
    [No Abstract]   [Full Text] [Related]  

  • 55. Human leukocyte antigens and drug hypersensitivity.
    Chung WH; Hung SI; Chen YT
    Curr Opin Allergy Clin Immunol; 2007 Aug; 7(4):317-23. PubMed ID: 17620823
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Validation of a rapid test for HLA-B*58:01/57:01 allele screening to detect individuals at risk for drug-induced hypersensitivity.
    Nguyen DV; Vidal C; Li J; Fulton RB; Fernando SL
    Pharmacogenomics; 2016 Apr; 17(5):473-80. PubMed ID: 27027663
    [TBL] [Abstract][Full Text] [Related]  

  • 57. HCP5 rs2395029 is a rapid and inexpensive alternative to HLA-B*57:01 genotyping to predict abacavir hypersensitivity reaction in Spain.
    Zubiaur P; Saiz-Rodríguez M; Villapalos-García G; Navares-Gómez M; Koller D; Abad-Santos F
    Pharmacogenet Genomics; 2021 Apr; 31(3):53-59. PubMed ID: 33044391
    [TBL] [Abstract][Full Text] [Related]  

  • 58. A study of HIV provider attitudes toward HLA-B 5701 testing in the United States.
    Watson ME; Patel LG; Ha B; Wannamaker P; Cuffe R; Shaefer M
    AIDS Patient Care STDS; 2009 Nov; 23(11):957-63. PubMed ID: 19839743
    [TBL] [Abstract][Full Text] [Related]  

  • 59. HLA alleles and drug hypersensitivity reactions.
    Profaizer T; Eckels D
    Int J Immunogenet; 2012 Apr; 39(2):99-105. PubMed ID: 22136512
    [TBL] [Abstract][Full Text] [Related]  

  • 60. HLA and drug-induced toxicity.
    Phillips EJ; Mallal SA
    Curr Opin Mol Ther; 2009 Jun; 11(3):231-42. PubMed ID: 19479656
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.